CORRECTED: Harwood Feffer LLP Announces It Has Amended Its Class Action Complaint Against Genzyme Corporation -- GENZ
29 1월 2011 - 1:59AM
Harwood Feffer LLP announced that on January 18, 2011 the firm
amended its class action complaint against Genzyme Corporation
("Genzyme Corporation" or the "Company") (Nasdaq:GENZ ) and its
Board of Directors to include claims of violations under Section 14
and Section 20 of the Securities Exchange Act of 1934.
The consolidated action, entitled In Re Genzyme Corporation
Shareholder Litigation, Master Docket No. 1:10-CV-11356, is pending
in the United States District Court for the District of
Massachusetts and names as defendants, Genzyme, the Company's
Chairman and CEO, Henri A. Termeer, and other members of the
Company's Board of Directors. A copy of the complaint can be
obtained from the Court.
The complaint charges that the defendants breached their
fiduciary duties to the Company's shareholders and violated the
Securities Exchange Act of 1934. More specifically, the complaint
alleges that defendants failed to disclose certain material facts
in connection with the proposal to acquire the Company by
Sanofi-Aventis, publicly announced on August 29, 2010, and that the
14D-9 defendants filed with the SEC on October 7, 2010 and
disseminated to Genzyme shareholders thereafter, wherein the Board
recommended shareholders not tender their shares, contained
materially misleading information. The complaint also includes
claims for breach of fiduciary duty. It is brought on behalf
of a class of all Genzyme shareholders except for the named
defendants and persons or entities related to or affiliated with
the defendants.
If you own Genzyme shares, you may request that the Court
appoint you as lead plaintiff by March 21, 2011 (an earlier release
incorrectly noted the deadline as April 18, 2011). A lead
plaintiff is a representative party that acts on behalf of other
class members in directing the litigation. In order to be appointed
lead plaintiff, the Court must determine that the class member's
claim is typical of the claims of other class members, and that the
class member will adequately represent the class. Under certain
circumstances, one or more class members may together serve as
"lead plaintiff." Your ability to share in any recovery is not,
however, affected by the decision whether or not to serve as a lead
plaintiff. You may retain Harwood Feffer, or other counsel of your
choice, to serve as your counsel in this action.
The Harwood Feffer LLP logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=454
Harwood Feffer has taken a leading role in many important
actions on behalf of defrauded shareholders. The Harwood Feffer
website (www.hfesq.com) has more information about the firm and
detailed information regarding this matter. If you wish to
discuss this action with us, or have any questions concerning this
notice or your rights and interests with regard to the case, please
contact the following:
Jeffrey M. Norton, Esq. |
Harwood Feffer LLP |
488 Madison Ave., 8th Floor |
New York, New York 10022 |
Toll Free Telephone: (877)
935-7400 |
jnorton@hfesq.com |
Genzyme (NASDAQ:GENZ)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Genzyme (NASDAQ:GENZ)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024